{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Esophagogastric+Cancer", "query": { "condition": "Esophagogastric Cancer" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 48, "total_pages": 5, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Esophagogastric+Cancer&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-05-22T07:48:47.352Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04034251", "title": "Intraperitoneal and Intravenous Paclitaxel Chemotherapy With Oral Capecitabine for Gastric Adenocarcinoma With Peritoneal Carcinomatosis", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Gastric Adenocarcinoma", "Gastric Cancer", "Esophagogastric Junction", "Peritoneal Carcinomatosis" ], "interventions": [ { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "BardPort Titanium Implanted Port with Peritoneal Catheter", "type": "DEVICE" } ], "intervention_types": [ "DRUG", "DEVICE" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 12, "start_date": "2020-06-09", "completion_date": "2024-09-05", "has_results": true, "last_update_posted_date": "2026-05-05", "last_synced_at": "2026-05-22T07:48:47.352Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT04034251" }, { "nct_id": "NCT01913639", "title": "FOLFOX Plus Regorafenib in Patients With Unresectable or Metastatic Esophagogastric Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Esophageal Cancer", "Gastric Cancer" ], "interventions": [ { "name": "Regorafenib", "type": "DRUG" }, { "name": "5-Fluorouracil", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 39, "start_date": "2013-07", "completion_date": "2019-06", "has_results": true, "last_update_posted_date": "2020-05-15", "last_synced_at": "2026-05-22T07:48:47.352Z", "location_count": 5, "location_summary": "Basking Ridge, New Jersey • Commack, New York • New York, New York + 2 more", "locations": [ { "city": "Basking Ridge", "state": "New Jersey" }, { "city": "Commack", "state": "New York" }, { "city": "New York", "state": "New York" }, { "city": "Rockville Centre", "state": "New York" }, { "city": "Sleepy Hollow", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01913639" }, { "nct_id": "NCT02954536", "title": "Phase II Trial of Pembrolizumab With Trastuzumab and Chemotherapy in Advanced HER2 Positive Esophagogastric (EG) Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Esophageal Cancer", "Gastric Cancer" ], "interventions": [ { "name": "pembrolizumab", "type": "DRUG" }, { "name": "trastuzumab", "type": "DRUG" }, { "name": "capecitabine", "type": "DRUG" }, { "name": "cisplatin", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "5-Fluorouracil", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 37, "start_date": "2016-11-03", "completion_date": "2023-03-14", "has_results": true, "last_update_posted_date": "2023-03-16", "last_synced_at": "2026-05-22T07:48:47.352Z", "location_count": 8, "location_summary": "Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 5 more", "locations": [ { "city": "Basking Ridge", "state": "New Jersey" }, { "city": "Middletown", "state": "New Jersey" }, { "city": "Montvale", "state": "New Jersey" }, { "city": "Commack", "state": "New York" }, { "city": "Harrison", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02954536" }, { "nct_id": "NCT04018872", "title": "Evaluating the Effect of Itraconazole on Pathologic Complete Response Rates in Esophageal Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Esophagus Adenocarcinoma", "Esophagus Squamous Cell Carcinoma", "Gastroesophageal Junction Adenocarcinoma" ], "interventions": [ { "name": "Itraconazole", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dallas VA Medical Center", "sponsor_class": "FED", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 78, "start_date": "2019-06-24", "completion_date": "2026-09-29", "has_results": false, "last_update_posted_date": "2021-11-04", "last_synced_at": "2026-05-22T07:48:47.352Z", "location_count": 1, "location_summary": "Dallas, Texas", "locations": [ { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04018872" }, { "nct_id": "NCT07132918", "title": "HEARTS Trial for Thoracic Cancers", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-Small Cell Lung Cancer (Stage III)", "Esophageal Cancer Stage I-III", "Esophagogastric Cancer Stage I-III", "Thymoma and Thymic Carcinoma Stage II-III", "Other Cancers in the Thoracic Region" ], "interventions": [ { "name": "MRgART", "type": "RADIATION" }, { "name": "LINAC", "type": "RADIATION" } ], "intervention_types": [ "RADIATION" ], "sponsor": "University of Wisconsin, Madison", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "2025-10-08", "completion_date": "2029-03", "has_results": false, "last_update_posted_date": "2026-03-11", "last_synced_at": "2026-05-22T07:48:47.352Z", "location_count": 1, "location_summary": "Madison, Wisconsin", "locations": [ { "city": "Madison", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT07132918" }, { "nct_id": "NCT04757363", "title": "A Study of Nivolumab Combined With FOLFOX and Regorafenib in People Who Have HER2-Negative Esophagogastric Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Esophagogastric Cancer", "HER2-Negative" ], "interventions": [ { "name": "regorafenib", "type": "DRUG" }, { "name": "nivolumab", "type": "DRUG" }, { "name": "FOLFOX chemotherapy with oxaliplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 39, "start_date": "2021-02-11", "completion_date": "2027-02", "has_results": false, "last_update_posted_date": "2026-03-04", "last_synced_at": "2026-05-22T07:48:47.352Z", "location_count": 7, "location_summary": "Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more", "locations": [ { "city": "Basking Ridge", "state": "New Jersey" }, { "city": "Middletown", "state": "New Jersey" }, { "city": "Montvale", "state": "New Jersey" }, { "city": "Commack", "state": "New York" }, { "city": "Harrison", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04757363" }, { "nct_id": "NCT05259696", "title": "Glycan Mediated Immune Regulation With a Bi-Sialidase Fusion Protein (GLIMMER-01)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Oncology", "Melanoma", "Ovarian Cancer", "NSCLC", "Non Small Cell Lung Cancer", "Colorectal Cancer", "Pancreatic Cancer", "Cancer", "CRC", "Colon Cancer", "Breast Cancer", "Gastric Cancer", "EGJ", "Esophagogastric Junction Cancer", "Head and Neck Cancer", "Urothelial Cancer", "Bladder Cancer" ], "interventions": [ { "name": "E-602", "type": "BIOLOGICAL" }, { "name": "Cemiplimab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Palleon Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 69, "start_date": "2022-02-11", "completion_date": "2024-10-24", "has_results": true, "last_update_posted_date": "2025-08-20", "last_synced_at": "2026-05-22T07:48:47.352Z", "location_count": 13, "location_summary": "La Jolla, California • Los Angeles, California • Stanford, California + 10 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT05259696" }, { "nct_id": "NCT02023996", "title": "PET Imaging With 89Zr-DFO-Trastuzumab in Esophagogastric Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Esophagogastric Cancer" ], "interventions": [ { "name": "89Zr-DFO-trastuzumab", "type": "RADIATION" }, { "name": "PET imaging", "type": "DEVICE" } ], "intervention_types": [ "RADIATION", "DEVICE" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 42, "start_date": "2013-12", "completion_date": "2023-06-27", "has_results": true, "last_update_posted_date": "2024-12-10", "last_synced_at": "2026-05-22T07:48:47.352Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02023996" }, { "nct_id": "NCT04656041", "title": "Folfox+Irinotecan+Chemort In Esophageal Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Gastroesophageal Junction Adenocarcinoma", "Esophagogastric Cancer" ], "interventions": [ { "name": "FOLFOX/ nal-IRI", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Proton Radiation Therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2021-06-29", "completion_date": "2027-12", "has_results": false, "last_update_posted_date": "2025-11-14", "last_synced_at": "2026-05-22T07:48:47.352Z", "location_count": 3, "location_summary": "Boston, Massachusetts • Newton, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Newton", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT04656041" }, { "nct_id": "NCT05705492", "title": "Olanzapine for the Management of Cancer Associated Appetite Loss in Patients With Advanced Esophagogastric, Hepatopancreaticobiliary, Colorectal or Lung Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Malignant Solid Neoplasm", "Advanced Biliary Tract Carcinoma", "Advanced Esophageal Carcinoma", "Metastatic Esophageal Carcinoma", "Locally Advanced Colorectal Carcinoma", "Locally Advanced Esophageal Carcinoma", "Locally Advanced Gastric Carcinoma", "Metastatic Colorectal Carcinoma (mCRC)", "Advanced Lung Carcinoma", "Locally Advanced Hepatocellular Carcinoma" ], "interventions": [ { "name": "Olanzapine", "type": "DRUG" }, { "name": "Placebo Administration", "type": "DRUG" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "OHSU Knight Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 66, "start_date": "2024-07-17", "completion_date": "2026-12-31", "has_results": false, "last_update_posted_date": "2026-01-21", "last_synced_at": "2026-05-22T07:48:47.352Z", "location_count": 1, "location_summary": "Portland, Oregon", "locations": [ { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT05705492" } ] }